CN114727965A - 一种jak激酶抑制剂药物组合物 - Google Patents
一种jak激酶抑制剂药物组合物 Download PDFInfo
- Publication number
- CN114727965A CN114727965A CN202080078667.7A CN202080078667A CN114727965A CN 114727965 A CN114727965 A CN 114727965A CN 202080078667 A CN202080078667 A CN 202080078667A CN 114727965 A CN114727965 A CN 114727965A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- lactose
- composition according
- lubricant
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 62
- 102000042838 JAK family Human genes 0.000 title abstract description 6
- 229940043355 kinase inhibitor Drugs 0.000 title abstract description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract description 4
- 239000008101 lactose Substances 0.000 claims abstract description 56
- 238000004090 dissolution Methods 0.000 claims abstract description 38
- 239000000463 material Substances 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- -1 3-methoxy-1, 2, 4-thiadiazole-5-yl Chemical group 0.000 claims abstract description 16
- 239000002131 composite material Substances 0.000 claims abstract description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 238000007922 dissolution test Methods 0.000 claims description 19
- 239000000945 filler Substances 0.000 claims description 19
- 239000000314 lubricant Substances 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 229910052751 metal Inorganic materials 0.000 claims description 15
- 239000007884 disintegrant Substances 0.000 claims description 14
- DNBCBAXDWNDRNO-FOSCPWQOSA-N (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide Chemical compound COC1=NSC(NC(=O)N2C[C@H]3CC(C[C@H]3C2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 DNBCBAXDWNDRNO-FOSCPWQOSA-N 0.000 claims description 12
- 239000012738 dissolution medium Substances 0.000 claims description 11
- 239000000377 silicon dioxide Substances 0.000 claims description 10
- 235000012239 silicon dioxide Nutrition 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 9
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 9
- 239000008117 stearic acid Substances 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 8
- 235000010980 cellulose Nutrition 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 240000008042 Zea mays Species 0.000 claims description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 6
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 235000005822 corn Nutrition 0.000 claims description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 3
- 102000015617 Janus Kinases Human genes 0.000 claims description 3
- 108010024121 Janus Kinases Proteins 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000001361 adipic acid Substances 0.000 claims description 3
- 235000011037 adipic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 229940049654 glyceryl behenate Drugs 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 230000000552 rheumatic effect Effects 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229960001375 lactose Drugs 0.000 description 41
- 239000002245 particle Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 239000011363 dried mixture Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012798 spherical particle Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种JAK激酶抑制剂药物组合物,含有(3aR,5s,6aS)‑N‑(3‑甲氧基‑1,2,4‑噻二唑‑5‑基)‑5‑(甲基(7H‑吡咯并[2,3‑d]嘧啶‑4‑基)氨基)六氢环戊并[c]吡咯‑2(1H)‑甲酰胺或其可药用盐和复合辅料如纤维素‑乳糖,具有良好的稳定性、溶出度和生物利用度且其制备工艺简便。
Description
PCT国内申请,说明书已公开。
Claims (18)
- PCT国内申请,权利要求书已公开。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311592893.9A CN117695285A (zh) | 2019-12-23 | 2020-12-22 | 一种jak激酶抑制剂药物组合物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911334601 | 2019-12-23 | ||
CN2019113346015 | 2019-12-23 | ||
PCT/CN2020/138253 WO2021129600A1 (zh) | 2019-12-23 | 2020-12-22 | 一种jak激酶抑制剂药物组合物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311592893.9A Division CN117695285A (zh) | 2019-12-23 | 2020-12-22 | 一种jak激酶抑制剂药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114727965A true CN114727965A (zh) | 2022-07-08 |
CN114727965B CN114727965B (zh) | 2023-12-12 |
Family
ID=76573677
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311592893.9A Pending CN117695285A (zh) | 2019-12-23 | 2020-12-22 | 一种jak激酶抑制剂药物组合物 |
CN202080078667.7A Active CN114727965B (zh) | 2019-12-23 | 2020-12-22 | 一种jak激酶抑制剂药物组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311592893.9A Pending CN117695285A (zh) | 2019-12-23 | 2020-12-22 | 一种jak激酶抑制剂药物组合物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230042525A1 (zh) |
EP (1) | EP4082533A1 (zh) |
JP (1) | JP2023508161A (zh) |
KR (1) | KR20220119466A (zh) |
CN (2) | CN117695285A (zh) |
AU (1) | AU2020414899A1 (zh) |
BR (1) | BR112022012363A2 (zh) |
CA (1) | CA3161463A1 (zh) |
TW (1) | TW202128177A (zh) |
WO (1) | WO2021129600A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024165036A1 (zh) * | 2023-02-07 | 2024-08-15 | 瑞石生物医药有限公司 | 一种局部给药的药物组合物、其制备方法及应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070059365A1 (en) * | 2003-08-22 | 2007-03-15 | Pollock Peta E | Novel formulation of ropinirole |
CN106511288A (zh) * | 2016-12-20 | 2017-03-22 | 天津泰普制药有限公司 | 一种非布司他片剂的制备方法 |
JP2017075139A (ja) * | 2016-09-05 | 2017-04-20 | 持田製薬株式会社 | 低用量薬物を含有する口腔内崩壊錠 |
CN106994120A (zh) * | 2016-01-22 | 2017-08-01 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
WO2017140254A1 (zh) * | 2016-02-19 | 2017-08-24 | 江苏恒瑞医药股份有限公司 | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 |
WO2019104225A1 (en) * | 2017-11-22 | 2019-05-31 | Dauntless 2, Inc. | Therapeutic compound formulations |
-
2020
- 2020-12-22 US US17/786,647 patent/US20230042525A1/en active Pending
- 2020-12-22 CN CN202311592893.9A patent/CN117695285A/zh active Pending
- 2020-12-22 WO PCT/CN2020/138253 patent/WO2021129600A1/zh active Application Filing
- 2020-12-22 KR KR1020227025456A patent/KR20220119466A/ko unknown
- 2020-12-22 CA CA3161463A patent/CA3161463A1/en active Pending
- 2020-12-22 JP JP2022538841A patent/JP2023508161A/ja active Pending
- 2020-12-22 CN CN202080078667.7A patent/CN114727965B/zh active Active
- 2020-12-22 AU AU2020414899A patent/AU2020414899A1/en active Pending
- 2020-12-22 TW TW109145562A patent/TW202128177A/zh unknown
- 2020-12-22 BR BR112022012363A patent/BR112022012363A2/pt not_active Application Discontinuation
- 2020-12-22 EP EP20904510.3A patent/EP4082533A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070059365A1 (en) * | 2003-08-22 | 2007-03-15 | Pollock Peta E | Novel formulation of ropinirole |
CN106994120A (zh) * | 2016-01-22 | 2017-08-01 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
WO2017140254A1 (zh) * | 2016-02-19 | 2017-08-24 | 江苏恒瑞医药股份有限公司 | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 |
JP2017075139A (ja) * | 2016-09-05 | 2017-04-20 | 持田製薬株式会社 | 低用量薬物を含有する口腔内崩壊錠 |
CN106511288A (zh) * | 2016-12-20 | 2017-03-22 | 天津泰普制药有限公司 | 一种非布司他片剂的制备方法 |
WO2019104225A1 (en) * | 2017-11-22 | 2019-05-31 | Dauntless 2, Inc. | Therapeutic compound formulations |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024165036A1 (zh) * | 2023-02-07 | 2024-08-15 | 瑞石生物医药有限公司 | 一种局部给药的药物组合物、其制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2023508161A (ja) | 2023-03-01 |
US20230042525A1 (en) | 2023-02-09 |
TW202128177A (zh) | 2021-08-01 |
CA3161463A1 (en) | 2021-07-01 |
WO2021129600A1 (zh) | 2021-07-01 |
KR20220119466A (ko) | 2022-08-29 |
CN117695285A (zh) | 2024-03-15 |
AU2020414899A1 (en) | 2022-07-14 |
BR112022012363A2 (pt) | 2022-08-30 |
CN114727965B (zh) | 2023-12-12 |
EP4082533A1 (en) | 2022-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240131026A1 (en) | Bromocriptine formulations | |
US6150366A (en) | Ziprasidone formulations | |
CN116367831A (zh) | 用于治疗由kdm1a介导的疾病的药物配制品 | |
AU2024204906A1 (en) | Acalabrutinib maleate dosage forms | |
CN114727965A (zh) | 一种jak激酶抑制剂药物组合物 | |
JP2015057422A (ja) | イルベサルタンを含有する錠剤 | |
JP6367042B2 (ja) | ボリコナゾールを含む医薬組成物 | |
WO2023093640A1 (zh) | 一种达罗他胺药物组合物及其制备方法和用途 | |
CN112294773B (zh) | 一种富马酸丙酚替诺福韦的药物组合物 | |
US20180344648A1 (en) | Clobazam tablet formulation and process for its preparation | |
CN113368073A (zh) | 制备用于降低血液尿酸水平的药物制剂的方法 | |
WO2015044394A1 (en) | Pharmaceutical composition comprising low dose active pharmaceutical ingredient and preparation thereof | |
JP2020015689A (ja) | レボセチリジン含有錠剤 | |
CN114246841B (zh) | 一种羟乙磺酸哌柏西利的组合物及药物 | |
WO2022042738A1 (zh) | 一种含cdk4/6抑制剂的药物组合物 | |
US20230172943A1 (en) | Oral solid meloxicam formulations for the treatment of acute pain | |
JP2011073972A (ja) | 混合粉体およびその製造方法、固形製剤 | |
WO2024085821A1 (en) | Content uniformity of teriflunomid in pharmaceutical dosage forms | |
CN116036038A (zh) | 一种苹果酸卡博替尼片剂及其制备方法 | |
CN113995728A (zh) | 一种药物组合物及制备方法 | |
CN114845723A (zh) | 包含喹唑啉衍生物或其盐的药物组合物 | |
JP2020015690A (ja) | レボセチリジン含有錠剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |